Related Experiment Video
Updated: Jun 5, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Pemetrexed in advanced non-small cell lung cancer
Cesare Gridelli1, Paolo Maione, Antonio Rossi
1S.G. Moscati Hospital, Division of Medical Oncology, Contrada Amoretta, 83100 Avellino, Italy. cgridelli@libero.it
Pemetrexed offers an innovative treatment for advanced non-squamous NSCLC, improving outcomes in first-line and maintenance therapy. This chemotherapy agent demonstrates a favorable safety profile, particularly when combined with cisplatin.
Area of Science:
- Oncology
- Pharmacology
Background:
- Advanced non-small cell lung cancer (NSCLC) presents significant treatment challenges.
- The development of novel, effective, and safe chemotherapeutic agents is crucial.
Purpose of the Study:
- To review the role of pemetrexed in the treatment of NSCLC.
- To elucidate the mechanism of action, safety, and clinical efficacy of pemetrexed.
Main Methods:
- Comprehensive review of clinical data on pemetrexed in NSCLC.
- Analysis of pemetrexed's efficacy in first-line, second-line, and maintenance settings.
- Clarification of the histotype-based approach for pemetrexed treatment selection.
Main Results:
- Pemetrexed has demonstrated efficacy in various treatment settings for advanced NSCLC.
- The drug is particularly effective in first-line and maintenance therapy for non-squamous NSCLC.
- Cisplatin plus pemetrexed combination shows a better safety profile than previous cisplatin-based regimens.
Conclusions:
- Pemetrexed represents a significant advancement in treating advanced non-squamous NSCLC.
- The combination of cisplatin and pemetrexed offers an improved safety profile for NSCLC patients.
More Related Videos
09:02Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017